Share on StockTwits

NanoViricides (NASDAQ:NNVC) Director Milton Boniuk purchased 57,144 shares of the stock on the open market in a transaction that occurred on Thursday, July 17th. The shares were purchased at an average price of $3.50 per share, with a total value of $200,004.00. Following the completion of the transaction, the director now directly owns 658,963 shares in the company, valued at approximately $2,306,371. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

NanoViricides (NASDAQ:NNVC) traded up 2.20% on Friday, hitting $4.65. 172,760 shares of the company’s stock traded hands. NanoViricides has a 52 week low of $2.67 and a 52 week high of $7.59. The stock’s 50-day moving average is $4.11 and its 200-day moving average is $3.93. The company’s market cap is $253.6 million.

NanoViricides (NASDAQ:NNVC) last issued its quarterly earnings data on Tuesday, May 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. On average, analysts predict that NanoViricides will post $-0.24 earnings per share for the current fiscal year.

Separately, analysts at Chardan Capital initiated coverage on shares of NanoViricides in a research note on Thursday, May 8th. They set a “buy” rating on the stock.

NanoViricides, Incis a development-stage company. The Company is a nano-biopharmaceutical (NASDAQ:NNVC) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.